All In Biotech

Drug Trial Radar · NCT02612311

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination With TGR-1202 (Umbralisib) Compared to Obinutuzumab in Combination With Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)

Last checked: Nov 19, 2026Latest source record: Dec 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 603 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

603

Actual

Start

Nov 19, 2015

Primary completion

Feb 22, 2023

Study completion Feb 22, 2023

Sponsor

Lead sponsor
TG Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 23, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the combination of ublituximab, a novel monoclonal antibody, and TGR-1202, a novel PI3K delta inhibitor compared to obinutuzumab and chlorambucil, and compared to ublituximab or TGR-1202 alone in Chronic Lymphocytic Leukemia (CLL) participants.

Conditions

  • Chronic Lymphocytic Leukemia

Interventions

  • ObinutuzumabBiological

    Obinutuzumab: IV infusion

  • UblituximabBiological

    Ublituximab: IV infusion

  • TGR-1202Drug

    TGR-1202: Oral daily dose

  • ChlorambucilDrug

    Chlorambucil: Oral dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) Per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) CriteriaTime frame: From enrolment to the earlier of the first documentation of definitive disease progression (PD) or death (Up to 87 months)

Locations

154 sites in 7 countries. Site status is shown where the registry gives one.

  • TG Therapeutics Investigational Trial Site

    Huntsville, Alabama

  • TG Therapeutics Investigational Trial Site

    Mobile, Alabama

  • TG Therapeutics Investigational Trial Site

    Chandler, Arizona

  • TG Therapeutics Investigational Trial Site

    Phoenix, Arizona

  • TG Therapeutics Investigational Trial Site

    Tucson, Arizona

  • TG Therapeutics Investigational Trial Site

    Fayetteville, Arkansas

  • TG Therapeutics Investigational Trial Site

    Concord, California

  • TG Therapeutics Investigational Trial Site

    Duarte, California

  • TG Therapeutics Investigational Trial Site

    Greenbrae, California

  • TG Therapeutics Investigational Trial Site

    Pismo Beach, California

  • TG Therapeutics Investigational Trial Site

    Pleasanton, California

  • TG Therapeutics Investigational Trial Site

    San Diego, California

  • TG Therapeutics Investigational Trial Site

    Santa Barbara, California

  • TG Therapeutics Investigational Trial Site

    Whittier, California

  • TG Therapeutics Investigational Trial Site

    Aurora, Colorado

  • TG Therapeutics Investigational Trial Site

    Denver, Colorado

  • TG Therapeutics Investigational Trial Site

    Bridgeport, Connecticut

  • TG Therapeutics Investigational Trial Site

    New Haven, Connecticut

  • TG Therapeutics Investigational Trial Site

    Stamford, Connecticut

  • TG Therapeutics Investigational Trial Site

    Newark, Delaware

  • TG Therapeutics Investigational Trial Site

    Boca Raton, Florida

  • TG Therapeutics Investigational Trial Site

    Fort Myers, Florida

  • TG Therapeutics Investigational Trial Site

    Jacksonville, Florida

  • TG Therapeutics Investigational Trial Site

    Jacksonville, Florida

  • TG Therapeutics Investigational Trial Site

    Ocala, Florida

  • TG Therapeutics Investigational Trial Site

    Pensacola, Florida

  • TG Therapeutics Investigational Trial Site

    St. Petersburg, Florida

  • TG Therapeutics Investigational Trial Site

    Tallahassee, Florida

  • TG Therapeutics Investigational Trial Site

    Tampa, Florida

  • TG Therapeutics Investigational Trial Site

    West Palm Beach, Florida

  • TG Therapeutics Investigational Trial Site

    Albany, Georgia

  • TG Therapeutics Investigational Trial Site

    Macon, Georgia

  • TG Therapeutics Investigational Trial Site

    Chicago, Illinois

  • TG Therapeutics Investigational Trial Site

    Decatur, Illinois

  • TG Therapeutics Investigational Trial Site

    Maywood, Illinois

  • TG Therapeutics Investigational Trial Site

    Niles, Illinois

  • TG Therapeutics Investigational Trial Site

    Peoria, Illinois

  • TG Therapeutics Investigational Trial Site

    Swansea, Illinois

  • TG Therapeutics Investigational Trial Site

    Urbana, Illinois

  • TG Therapeutics Investigational Trial Site

    Fort Wayne, Indiana

Showing 40 of 154 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.